<DOC>
	<DOCNO>NCT00084318</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy , cisplatin docetaxel , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Cisplatin docetaxel may make tumor cell sensitive radiation therapy . Combining monoclonal antibody chemoradiotherapy give surgery may kill remain tumor cell . PURPOSE : This randomized phase II trial study adjuvant cetuximab give together chemoradiotherapy use cisplatin see well work compare adjuvant cetuximab give together chemoradiotherapy use docetaxel treat patient resect stage III stage IV squamous cell carcinoma ( cancer ) lymphoepithelioma head neck .</brief_summary>
	<brief_title>Adjuvant Cetuximab Chemoradiotherapy Using Either Cisplatin Docetaxel Treating Patients With Resected Stage III Stage IV Squamous Cell Carcinoma Lymphoepithelioma Head Neck</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare disease-free survival patient resect stage III IV squamous cell carcinoma lymphoepithelioma head neck treat adjuvant cetuximab combination chemoradiotherapy comprise docetaxel v cisplatin . Secondary - Compare safety efficacy regimens patient . - Compare locoregional control overall survival rate patient treat regimen . - Correlate epidermal growth factor receptor ( total phosphorylated ) , pMAPK , pAKT , Stat-3 , Ki-67 , cyclo-oxygenase-2 , cyclin B1 expression outcome patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord Zubrod performance status ( 0 vs 1 ) , risk category ( positive margin vs high risk [ i.e. , ≥ 2 positive node extracapsular nodal extension ] ) use intensity-modulated radiotherapy ( vs yes ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cetuximab IV 2 hour day 1 ( week 1 ) . Patients receive cetuximab IV 1 hour cisplatin IV 1 hour radiotherapy day 8 , 15 , 22 , 29 , 36 , 43 ( week 2-7 ) . Patients undergo radiotherapy daily , 5 day week , begin day 8 total 6 week ( week 2-7 ) . - Arm II : Patients receive cetuximab undergo radiotherapy arm I . Patients also receive docetaxel IV 30 minute radiotherapy day 8 , 15 , 22 , 29 , 36 , 43 ( week 2-7 ) . Treatment arm continue absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 230 patient ( 115 per treatment arm ) accrue study within approximately 29 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck meet follow criterion : Site tumor origin oral cavity , oropharynx , larynx , hypopharynx ( exclude lip , nasopharynx , sinus ) Gross total resection must complete within 7 week randomization , pathology demonstrate one follow risk factor : Histologic extracapsular nodal extension Histologic involvement ≥ 2 regional lymph node Invasive cancer see microscopic evaluation resection margin , evidence gross tumor residual . Tonsillar cancer patient undergo transoral excision gross tumor eligible provide extracapsular nodal extension involvement ≥ 2 regional lymph node histologically confirm American Joint Committee Cancer ( AJCC ) pathological stage III IV No evidence distant metastases No synchronous concurrent head neck primary tumor PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin &gt; 8.0 g/dL Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) , alkaline phosphatase meeting 1 follow parameter : Alkaline phosphatase ≤ ULN AND AST ALT ≤ 5 time ULN Alkaline phosphatase ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN Alkaline phosphatase ≤ 5 time ULN AND AST ALT ≤ ULN Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No unstable angina No uncontrolled hypertension No myocardial infarction within past 6 month ( unless successfully treat coronary artery bypass surgery percutaneous transluminal coronary angioplasty ) No uncontrolled arrhythmia No congestive heart failure No 2 heartrelated hospitalization within past year No active cardiac disease Pulmonary No 2 hospitalization chronic obstructive pulmonary disease within past year Neurologic No preexist peripheral neuropathy ≥ grade 2 No uncontrolled seizure disorder No active neurological disease Other No prior severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No invasive malignancy within past 3 year except nonmelanoma skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior antiepidermal growth factor receptor antibody therapy Chemotherapy More 3 year since prior cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy No prior head neck radiotherapy Surgery See Disease Characteristics Other No prior tyrosine kinase inhibitor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
</DOC>